| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 |
| 04 Nov 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.2 Pioneering a New Era of GPCR Drug Discovery Corporate Presentation November 2026 Nasdaq: SEPN © 2026 SEPTERNA |
| 25 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
SOUTH SAN FRANCISCO, Calif. – August 25, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patn... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist |
| 30 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Septerna, Inc. (the “Company”), held on June 26, 2026 (the “Annual Meeting”). |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support |
| 13 Apr 2026 |
8-K: Regulation FD Disclosure
Pioneering a New Era of GPCR Drug Discovery April 2026 Nasdaq: SEPN Corporate Presentation Exhibit 99.2 |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 |
| 02 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Phase 1 Results* for SEP-631, a Novel Oral Small Molecule MRGPRX2 Negative Allosteric Modulator (NAM) for Mast Cell-Driven Diseases March 2, 2026 Nasdaq: SEPN *Data presented at the 2026 American Academy of Allergy Asthma & ... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Pioneering a New Era of GPCR Drug Discovery J.P. Morgan Healthcare Conference 2026 January 2026 Nasdaq: SEPN |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., JANUARY 8, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wil... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate |
| 29 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif. – Sept. 29, 2025 – Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gotte... |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure
Nasdaq: SEPN Pioneering a New Era of GPCR Drug Discovery September 2025 Corporate Presentation Exhibit 99.1 |
| 21 Aug 2025 |
8-K: Regulation FD Disclosure
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development |
| 04 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 30, 2025, the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) appointed Liz Bhatt, M.S., M.B.A., the Company’s Chief Operating Officer, to serve as the Company’s President, in addition to continuing in her curr... |
| 02 Jul 2025 |
8-K: Other Events
On July 1, 2025, the previously announced Collaboration and License Agreement, dated as of May 13, 2025 (the “Collaboration Agreement”), by and between Septerna, Inc. (the “Company”) and Novo Nordisk A/S, became effective following the e... |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Septerna, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments |
Loading...